APA (7th ed.) Citation

Yang, J., Song, Y., Zhou, K., Li, Z., Zhang, M., Jing, H., . . . Shi, Y. (2024). Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: A phase 1/2 study. Journal of Hematology & Oncology, 17(1), 1. https://doi.org/10.1186/s13045-024-01646-2

Chicago Style (17th ed.) Citation

Yang, Jianliang, et al. "Safety and Efficacy of Amulirafusp Alfa (IMM0306), a Fusion Protein of CD20 Monoclonal Antibody with the CD47 Binding Domain of SIRPα, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma: A Phase 1/2 Study." Journal of Hematology & Oncology 17, no. 1 (2024): 1. https://doi.org/10.1186/s13045-024-01646-2.

MLA (9th ed.) Citation

Yang, Jianliang, et al. "Safety and Efficacy of Amulirafusp Alfa (IMM0306), a Fusion Protein of CD20 Monoclonal Antibody with the CD47 Binding Domain of SIRPα, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma: A Phase 1/2 Study." Journal of Hematology & Oncology, vol. 17, no. 1, 2024, p. 1, https://doi.org/10.1186/s13045-024-01646-2.